Skip to main content
Evidence Snapshot

Vasopressin V2 receptor

CHEMBL1790 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1790
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vasopressin V2 receptor as ChEMBL target CHEMBL1790, mapped to UniProt P30518. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vasopressin V2 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1790
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30518
Vasopressin V2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Vasopressin V2 receptor matters

As of 2026-09-13

Vasopressin V2 receptor is reviewed as Vasopressin V2 receptor (UniProt P30518); Vasopressin V2 receptor shows approved-linked disease relevance led by Hyponatremia. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 2361 compounds, and 296 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Hyponatremia

Vasopressin V2 receptor shows approved-linked disease relevance led by Hyponatremia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CONIVAPTAN HYDROCHLORIDE, LIXIVAPTAN, SATAVAPTAN.

Start review with Hyponatremia because it currently carries approved-linked support. Linked drugs include CONIVAPTAN HYDROCHLORIDE, LIXIVAPTAN, SATAVAPTAN, TOLVAPTAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 2361 compounds, and 296 assays for this target. The dominant activity type is IC50. CHEMBL373742 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL373742 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Vasopressin V2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30518, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Hyponatremia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2361
Total Compounds
296
Total Assays
16
Approved Drugs
IC50: 618.0, KI: 606.0, EC50: 410.0, KD: 10.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL373742
 10.3 EC50 Approved
No preferred name
CHEMBL435323
 10.3 EC50 —
No preferred name
CHEMBL4454891
 10.1 EC50 —
No preferred name
CHEMBL4528032
 10.0 EC50 —
No preferred name
CHEMBL4536454
 10.0 EC50 —

Approved Drugs

Structure Compound First Approval
VASOPRESSIN
CHEMBL373742
 2014
TOLVAPTAN
CHEMBL344159
 2009
MOZAVAPTAN
CHEMBL420762
 2006
CONIVAPTAN
CHEMBL1755
 2005
ATOSIBAN
CHEMBL382301
 2000
ITRACONAZOLE
CHEMBL64391
 1992
OXYTOCIN
CHEMBL395429
 1980
DESMOPRESSIN
CHEMBL1429
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1790